# Consolidated Financial Results <br> for the Third Quarter of the Fiscal Year Ending February 28, 2018 <br> (Nine Months Ended November 30, 2017) 

|  |  | [Japanese GAAP] |
| :--- | :--- | :--- |
| Company name: | Freund Corporation | Listing: Tokyo (JASDAQ) |
| Securities code: | 6312 | URL: http://www.freund.co.jp |
| Representative: | Iwao Fusejima, President \& CEO |  |
| Contact: | Yuji Takanami, General Manager, Corporate Administration Division |  |
|  | Tel: $+81-3-6890-0750$ |  |
| Scheduled date of filing of Quarterly Report: | January 10, 2018 |  |
| Scheduled date of payment of dividend: | - |  |
| Preparation of supplementary materials for quarterly financial results: None | None |  |
| Holding of quarterly financial results meeting: | (All amounts are rounded down to the nearest million yen) |  |

1. Consolidated Financial Results for the Third Quarter (March 1, 2017 - November 30, 2017) of the Fiscal Year Ending February 28, 2018
(1) Consolidated results of operations

Listing: Tokyo (JASDAQ)
Frerporation
6312
URL: http://www.freund.co.jp
Representative: Iwao Fusejima, President \& CEO
Contact: Yuji Takanami, General Manager, Corporate Administration Division Tel: +81-3-6890-0750
Scheduled date of filing of Quarterly Report:
January 10, 2018
Scheduled date of payment of dividend:
None
$\begin{array}{ll}\text { Preparation of supplementary materials for quarterly financial results. None } \\ \text { Holding of quarterly financial results meeting: } & \text { None }\end{array}$
(All amounts are rounded down to the nearest million yen)

| (1) Consolidated results of operations |  |  |  |  | Percentages represent year-on-year changes) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Net sales |  | Operating profit |  | Ordinary profit |  | Profit attributable to owners of parent |  |
|  | Million yen | \% | Million yen | \% | Million yen | \% | Million yen | \% |
| Nine months ended Nov. 30, 2017 | 13,745 | (6.9) | 1,152 | (20.0) | 1,174 | (21.0) | 849 | 4.1 |
| Nine months ended Nov. 30, 2016 | 14,767 | 12.9 | 1,441 | 98.2 | 1,486 | 89.6 | 815 | 93.1 |

Note: Comprehensive income Nine months ended Nov. 30, 2017: 847 million yen (up 78.5\%)
Nine months ended Nov. 30, 2016: 474 million yen (up 33.0\%)

|  | Net income per share | Diluted net income per share |
| :--- | ---: | ---: |
|  | Yen | Yen |
| Nine months ended Nov. 30, 2017 | 49.26 | - |
| Nine months ended Nov. 30, 2016 | 47.30 | - |

(2) Consolidated financial position

|  | Total assets | Net assets | Equity ratio | Net assets per share |
| :--- | ---: | ---: | ---: | ---: |
|  | Million yen | Million yen | $\%$ | Yen |
| As of Nov. 30, 2017 | 19,755 | 12,688 | 64.2 | 735.78 |
| As of Feb. 28, 2017 | 19,101 | 12,185 | 63.8 | 706.62 |

Reference: Equity capital
As of Nov. 30, 2017: 12,688 million yen
As of Feb. 28, 2017: $\quad 12,185$ million yen
2. Dividends

|  | Dividend per share |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q-end | 2Q-end | 3Q-end | Year-end | Total |
|  | Yen | Yen | Yen | Yen | Yen |
| Fiscal year ended Feb. 28, 2017 | - | 0.00 | - | 20.00 | 20.00 |
| Fiscal year ending Feb. 28, 2018 | - | 0.00 | - |  |  |
| Fiscal year ending Feb. 28, 2018 (forecast) |  |  |  | 20.00 | 20.00 |
| Note: Revision to the most recently announ | dividend fore | None |  |  |  |
| Breakdown of the year-end dividend for the | l year ended | 28, 2017: O | ary dividends | 15.00 ye |  |
|  |  |  | nemorative divis | ends: 5.00 ye |  |

## 3. Consolidated Forecast for the Fiscal Year Ending February 28, 2018 (March 1, 2017 - February 28, 2018)

(Percentages represent year-on-year changes)

|  | Net sales |  | Operating profit |  | Ordinary profit |  | Profag attributable <br> to owners of parent |  | Net income per <br> share |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: |
|  | Million yen |  | $\%$ | Million yen | $\%$ | Million yen | $\%$ | Million yen | $\%$ |  |
| Yull year | 21,000 | $(0.8)$ | 2,100 | 2.9 | 2,100 | 0.1 | 1,400 | 31.5 | 81.19 |  |

Note: Revision to the most recently announced consolidated forecast: None

## * Notes

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in changes in scope of consolidation): None
Newly added: - Excluded: -
(2) Application of special accounting methods for presenting quarterly consolidated financial statements: Yes

Note: Please refer to page 8 "(3) Application of Special Accounting Methods for Presenting Quarterly Consolidated Financial Statements" for details.
(3) Changes in accounting policies and accounting-based estimates, and restatements

1) Changes in accounting policies due to revisions in accounting standards, others: None
2) Changes in accounting policies other than 1) above: None
3) Changes in accounting-based estimates: None
4) Restatements: None
(4) Number of outstanding shares (common stock)
5) Number of shares outstanding at the end of the period (including treasury shares)

As of Nov. 30, 2017: 18,400,000 shares As of Feb. 28, 2017: 18,400,000 shares
2) Number of treasury shares at the end of the period
As of Nov. 30, 2017: $\quad 1,155,478$ shares $\quad$ As of Feb. 28, 2017: 1,155,478 shares
3) Average number of shares outstanding during the period

Nine months ended Nov. 30, 2017: 17,244,522 shares Nine months ended Nov. 30, 2016: 17,244,538 shares
The current quarterly financial report is not subject to the quarterly review procedures based on the Financial Instruments and Exchange Act. At the time of disclosure, the review procedures for the quarterly financial statements have been completed.

The current financial report is not subject to the quarterly review procedures.

Cautionary statement with respect to forecasts of future performance and other special items
Forecasts regarding future performance in these materials are based on certain assumptions judged to be valid and information currently available to the Company. Actual performance may differ significantly from these forecasts for a number of reasons. Please refer to the section "Explanation of Consolidated Forecast and Other Forward-looking Statements" on page 3 of the attachments regarding preconditions or other related matters for forecasts shown above.

## Contents of Attachments

1. Qualitative Information on Quarterly Consolidated Financial Performance ..... 2
(1) Explanation of Results of Operations ..... 2
(2) Explanation of Financial Position ..... 3
(3) Explanation of Consolidated Forecast and Other Forward-looking Statements ..... 3
2. Quarterly Consolidated Financial Statements and Notes ..... 4
(1) Quarterly Consolidated Balance Sheet ..... 4
(2) Quarterly Consolidated Statements of Income and Comprehensive Income ..... 6
Quarterly Consolidated Statement of Income
For the Nine-month Period ..... 6
Quarterly Consolidated Statement of Comprehensive Income
For the Nine-month Period ..... 7
(3) Notes to Quarterly Consolidated Financial Statements ..... 8
Going Concern Assumption ..... 8
Significant Changes in Shareholders' Equity ..... 8
Application of Special Accounting Methods for Presenting Quarterly Consolidated Financial Statements ..... 8
Additional Information ..... 8
Segment and Other Information ..... 9
3. Supplementary Information ..... 11
Orders and Sales ..... 11

## 1. Qualitative Information on Quarterly Consolidated Financial Performance

## (1) Explanation of Results of Operations

Japan's economy continued to recover slowly during the first nine months of the fiscal year due to an improvement in corporate earnings and firm employment and personal income.
However, the outlook continues to be unclear because of a number of risk factors that could negatively affect Japan's economy. In particular, Japan may be affected by financial market instability caused by the uncertainty about policies of the U.S. government and rising global tension concerning North Korea.

The pharmaceutical industry, which is the primary source of demand for Freund Group products, has been growing more slowly, mainly in industrialized countries. Causes include more Japanese government actions to hold down healthcare expenditures, such as national health insurance drug price revisions and measures to increase the use of generic drugs, as well as the rising cost of R\&D and higher risks associated with the development of new drugs. Consequently, the focus of attention in the pharmaceutical industry is shifting to emerging countries and to the expansion of the market for generic drugs.

Generic drug companies are making substantial capital expenditures as governments implement policies to increase the use of these drugs. Although Freund's performance has benefited from these expenditures, generic drug companies are holding down their capital expenditures in response to drug price reductions.
The Freund Group has developed innovative new products and worked on precisely targeting customers' needs. Group companies also aggressively pursued opportunities in new business fields.

Net sales decreased $6.9 \%$ year-over-year to 13,745 million yen, operating profit decreased $20.0 \%$ to 1,152 million yen, ordinary profit was down $21.0 \%$ to 1,174 million yen, and profit attributable to owners of parent increased $4.1 \%$ to 849 million yen.

Results by business segment were as follows.

## Machinery Business Segment

In the machinery sector, where granulating and coating devices are the main products, sales and operating profit decreased. The main reasons were the measures to hold down capital expenditures by generic drug companies and, at U.S. subsidiary Freund-Vector Corporation, a large order with low profitability and an increase in fixed expenses.

As a result, net sales decreased $2.6 \%$ year-over-year to 9,747 million yen and operating profit decreased $21.1 \%$ to 910 million yen.

## Chemicals Business Segment

Sales and operating profit of functional excipients used in oral pharmaceuticals increased mainly because of higher sales to manufacturers of generic drugs.

Sales and operating profit of food preservative increased because of aggressive marketing efforts.
Sales and operating profit of dietary supplements that incorporate Freund's technologies decreased because a major customer started producing supplements internally.

As a result, net sales decreased $16.1 \%$ year-over-year to 3,998 million yen and operating profit decreased $1.4 \%$ to 593 million yen.

## (2) Explanation of Financial Position

## Assets, liabilities and net assets

Total assets increased 653 million yen from the end of the previous fiscal year to 19,755 million yen at the end of the third quarter under review. This mainly reflected increases in work in process of 1,240 million yen and electronically recorded monetary claims-operating of 252 million yen, while there were decreases in cash and deposits of 590 million yen and notes and accounts receivable-trade of 313 million yen.

Total liabilities increased 151 million yen from the end of the previous fiscal year to 7,067 million yen at the end of the third quarter under review. This mainly reflected an increase in advances received of 606 million yen while there were decreases in income taxes payable of 291 million yen and provision for bonuses of 139 million yen.

Net assets increased 502 million yen from the end of the previous fiscal year to 12,688 million yen at the end of the third quarter under review.

## (3) Explanation of Consolidated Forecast and Other Forward-looking Statements

There are no revisions to the full year consolidated forecasts for the fiscal year ending February 28, 2018, which was disclosed in the Consolidated Financial Results for the Fiscal Year Ended February 28, 2017 dated April 5, 2017.

## 2. Quarterly Consolidated Financial Statements and Notes

(1) Quarterly Consolidated Balance Sheet

|  | (Thousands of yen) |  |
| :---: | :---: | :---: |
|  | $\begin{gathered} \text { FY2/17 } \\ (\text { As of Feb. } 28,2017) \end{gathered}$ | Third quarter of FY2/18 (As of Nov. 30, 2017) |
| Assets |  |  |
| Current assets |  |  |
| Cash and deposits | 6,982,822 | 6,392,780 |
| Notes and accounts receivable-trade | 4,282,766 | 3,968,794 |
| Electronically recorded monetary claims-operating | 120,616 | 372,932 |
| Merchandise and finished goods | 404,081 | 300,789 |
| Work in process | 1,712,294 | 2,952,990 |
| Raw materials and supplies | 649,160 | 807,822 |
| Prepaid expenses | 148,338 | 105,032 |
| Deferred tax assets | 251,999 | 275,960 |
| Other | 400,079 | 351,328 |
| Allowance for doubtful accounts | $(13,507)$ | $(13,446)$ |
| Total current assets | 14,938,653 | 15,514,984 |
| Non-current assets |  |  |
| Property, plant and equipment |  |  |
| Buildings and structures, net | 1,160,332 | 1,107,293 |
| Land | 1,239,987 | 1,239,893 |
| Other, net | 834,614 | 1,008,483 |
| Total property, plant and equipment | 3,234,934 | 3,355,670 |
| Intangible assets | 55,836 | 20,859 |
| Investments and other assets |  |  |
| Deferred tax assets | 15,073 | 17,933 |
| Other | 862,443 | 851,488 |
| Allowance for doubtful accounts | $(5,400)$ | $(5,400)$ |
| Total investments and other assets | 872,116 | 864,022 |
| Total non-current assets | 4,162,887 | 4,240,551 |
| Total assets | 19,101,540 | 19,755,536 |
| Liabilities |  |  |
| Current liabilities |  |  |
| Notes and accounts payable-trade | 2,019,656 | 2,261,368 |
| Electronically recorded obligations-operating | 1,038,971 | 1,011,914 |
| Income taxes payable | 477,303 | 185,939 |
| Advances received | 1,831,994 | 2,438,072 |
| Provision for bonuses | 260,416 | 121,044 |
| Provision for directors' bonuses | 85,400 | 58,500 |
| Other | 878,731 | 654,523 |
| Total current liabilities | 6,592,473 | 6,731,363 |
| Non-current liabilities |  |  |
| Net defined benefit liability | 201,812 | 210,869 |
| Asset retirement obligations | 34,824 | 34,939 |
| Other | 87,072 | 90,199 |
| Total non-current liabilities | 323,709 | 336,008 |
| Total liabilities | 6,916,182 | 7,067,371 |


|  | (Thousands of yen) |  |
| :---: | :---: | :---: |
|  | $\begin{gathered} \text { FY2/17 } \\ \text { (As of Feb. 28, 2017) } \end{gathered}$ | Third quarter of FY2/18 (As of Nov. 30, 2017) |
| Net assets |  |  |
| Shareholders' equity |  |  |
| Capital stock | 1,035,600 | 1,035,600 |
| Capital surplus | 1,289,513 | 1,289,513 |
| Retained earnings | 10,286,711 | 10,791,307 |
| Treasury shares | (201,361) | $(201,361)$ |
| Total shareholders' equity | 12,410,463 | 12,915,059 |
| Accumulated other comprehensive income |  |  |
| Valuation difference on available-for-sale securities | 33,141 | 40,284 |
| Foreign currency translation adjustment | $(233,036)$ | $(244,116)$ |
| Remeasurements of defined benefit plans | $(25,210)$ | $(23,063)$ |
| Total accumulated other comprehensive income | $(225,105)$ | $(226,895)$ |
| Total net assets | 12,185,358 | 12,688,164 |
| Total liabilities and net assets | 19,101,540 | 19,755,536 |

## (2) Quarterly Consolidated Statements of Income and Comprehensive Income

## Quarterly Consolidated Statement of Income

## (For the Nine-month Period)

|  | (Thousands of yen) |  |
| :---: | :---: | :---: |
|  | First nine months of FY2/17 (Mar. 1, 2016 - Nov. 30, 2016) | First nine months of FY2/18 (Mar. 1, 2017 - Nov. 30, 2017) |
| Net sales | 14,767,069 | 13,745,942 |
| Cost of sales | 10,069,748 | 8,993,321 |
| Gross profit | 4,697,320 | 4,752,621 |
| Selling, general and administrative expenses | 3,256,281 | 3,599,836 |
| Operating profit | 1,441,039 | 1,152,784 |
| Non-operating income |  |  |
| Interest income | 1,706 | 2,062 |
| Technical support fee | 11,600 | 10,670 |
| Insurance premiums refunded cancellation | 18,424 | - |
| Other | 20,499 | 17,703 |
| Total non-operating income | 52,231 | 30,436 |
| Non-operating expenses |  |  |
| Interest expenses | 1,937 | 1,259 |
| Foreign exchange losses | 2,399 | 5,169 |
| Other | 1,984 | 2,253 |
| Total non-operating expenses | 6,321 | 8,682 |
| Ordinary profit | 1,486,950 | 1,174,538 |
| Extraordinary income |  |  |
| Gain on sales of non-current assets | 7,655 | - |
| Gain on sales of investment securities | 14,936 | - |
| Gain on redemption of investment securities | - | 62,177 |
| Total extraordinary income | 22,591 | 62,177 |
| Extraordinary losses |  |  |
| Loss on retirement of non-current assets | 1,045 | 336 |
| Loss on sales of non-current assets | - | 1,923 |
| Impairment loss | 1,616 | - |
| Directors' retirement benefits | 250,000 | - |
| Total extraordinary losses | 252,661 | 2,259 |
| Profit before income taxes | 1,256,879 | 1,234,457 |
| Income taxes | 441,210 | 384,970 |
| Profit | 815,669 | 849,486 |
| Profit attributable to owners of parent | 815,669 | 849,486 |

## Quarterly Consolidated Statement of Comprehensive Income

(For the Nine-month Period)

|  | (Thousands of yen) |  |
| :---: | :---: | :---: |
|  | First nine months of FY2/17 <br> (Mar. 1, 2016 - Nov. 30, 2016) | First nine months of FY2/18 <br> (Mar. 1, 2017 - Nov. 30, 2017) |
| Profit | 815,669 | 849,486 |
| Other comprehensive income |  |  |
| Valuation difference on available-for-sale securities | 2,818 | 7,143 |
| Foreign currency translation adjustment | $(344,976)$ | $(11,080)$ |
| Remeasurements of defined benefit plans, net of tax | 1,299 | 2,147 |
| Total other comprehensive income | $(340,857)$ | $(1,789)$ |
| Comprehensive income | 474,811 | 847,696 |
| Comprehensive income attributable to |  |  |
| Comprehensive income attributable to owners of parent | 474,811 | 847,696 |

(3) Notes to Quarterly Consolidated Financial Statements

## Going Concern Assumption

Not applicable.

Significant Changes in Shareholders' Equity
Not applicable.

## Application of Special Accounting Methods for Presenting Quarterly Consolidated Financial Statements

## Calculation of tax expense

The tax expenses are calculated by first estimating the effective tax rate after the application of tax effect accounting with respect to profit before income taxes during the fiscal year in which the period under review falls, and multiplying that rate by the profit before income taxes for the period under review. However, the Company uses the statutory effective tax rate to calculate tax expenses for cases in which using the estimated tax rate gives a noticeably irrational result.

## Additional Information

Effective from the first quarter of the current fiscal year, the Company has applied the "Implementation Guidance on Recoverability of Deferred Tax Assets" (Accounting Standards Board of Japan (ASBJ) Guidance No. 26, March 28, 2016).

## Segment and Other Information

## Segment information

I First nine months of FY2/17 (Mar. 1, 2016 - Nov. 30, 2016)

1. Information related to net sales and profit or loss for each reportable segment

|  | Machinery Business | Chemicals Business | Total | Adjustment <br> (Note 1) | Amounts shwon on quarterly consolidated statement of income (Note 2) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales <br> (1) External sales <br> (2) Inter-segment sales and transfers | 10,003,630 | $4,763,438$ | $14,767,069$ | - | 14,767,069 |
| Total | 10,003,630 | 4,763,438 | 14,767,069 | - | 14,767,069 |
| Segment profit | 1,154,303 | 602,091 | 1,756,395 | $(315,355)$ | 1,441,039 |

Notes: 1. Contents of adjustments are as follows.
The negative adjustment of 315,355 thousand yen to segment profit includes corporate expenses that are not allocated to any of the reportable segments. Corporate expenses mainly consist of general and administrative expenses that are not attributable to any of the reportable segments.
2. Segment profit is adjusted to be consistent with operating profit recorded in the quarterly consolidated statement of income.
2. Information related to impairment losses on non-current assets, goodwill, etc. for each reportable segment

Significant change in goodwill
In the Machinery Business segment, the cumulative effect at the beginning of the first quarter of FY2/17 upon the retrospective adoption of the Accounting Standard for Business Combinations, etc. for prior years is added to or deducted from capital surplus and retained earnings. As a result, goodwill decreased 77,159 thousand yen at the beginning of the first quarter of FY2/17.

## 3. Information by region

## Net sales

In addition to the disclosure of information required by the "Accounting Standard for Quarterly Financial Statements," the Company provides information by region (net sales) based on the "Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" for the purpose of providing investors with useful information.

|  | (Thousands of yen) |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Japan | North America | Latin America | Europe | Other | Total |
| $11,725,000$ | $1,645,760$ | 261,088 | 423,717 | 711,500 | $14,767,069$ |

Notes: 1. Classification of net sales is based on the location of the client and categorized by country or region.
2. Groupings of countries and regions other than Japan are determined by geographic proximity and mutual operational relationships. Major countries and regions in each geographic segment are as follows.
(1) North America: US and Canada
(2) Latin America: Brazil, etc.
(3) Europe:

France, UK, etc.
(4) Other:

Asia, etc.

II First nine months of FY2/18 (Mar. 1, 2017 - Nov. 30, 2017)

1. Information related to net sales and profit or loss for each reportable segment
(Thousands of yen)

|  | Machinery <br> Business | Chemicals <br> Business | Total | Adjustment <br> (Note 1) | Amounts shwon on <br> quarterly consolidated <br> statement of income <br> (Note 2) |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Net sales <br> (1) External sales <br> (2) Inter-segment sales and <br> transfers | $9,747,293$ | $3,998,649$ | $13,745,942$ | - | - |
| Total | - | - | - | - | $-13,745,942$ |
| Segment profit | $9,747,293$ | $3,998,649$ | $13,745,942$ | - | - |

Notes: 1. Contents of adjustments are as follows.
The negative adjustment of 351,931 thousand yen to segment profit includes corporate expenses that are not allocated to any of the reportable segments. Corporate expenses mainly consist of general and administrative expenses that are not attributable to any of the reportable segments.
2. Segment profit is adjusted to be consistent with operating profit recorded in the quarterly consolidated statement of income.
2. Information related to impairment losses on non-current assets, goodwill, etc. for each reportable segment

Not applicable.

## 3. Information by region

Net sales
In addition to the disclosure of information required by the "Accounting Standard for Quarterly Financial Statements," the Company provides information by region (net sales) based on the "Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" for the purpose of providing investors with useful information.

| Japan | North America | Latin America | Europe | Other | Total |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $9,771,354$ | $1,297,648$ | 497,498 | $1,289,312$ | 890,128 | $13,745,942$ |

Notes: 1. Classification of net sales is based on the location of the client and categorized by country or region.
2. Groupings of countries and regions other than Japan are determined by geographic proximity and mutual operational relationships. Major countries and regions in each geographic segment are as follows.
(1) North America:
US and Canada
(2) Latin America:
(3) Europe:
France, UK, etc.
(4) Other:
Asia, etc.

## 3. Supplementary Information

## Orders and Sales

(1) Orders received
(Thousands of yen)

| Operating segment First nine months of FY2/17 <br> (Mar. 1, 2016 - Nov. 30, 2016)  First nine months of FY2/18 <br> (Mar. 1, 2017 - Nov. 30, 2017)  <br>  Amount    Year-on-year (\%) | Amount | Year-on-year (\%) |  |  |
| :--- | ---: | ---: | ---: | ---: |
|  | $12,243,473$ | 126.6 | $8,747,449$ | 71.4 |
| Chemicals Business | $1,733,988$ | 107.5 | 477,635 | 27.5 |
| Total | $13,977,461$ | 123.9 | $9,225,085$ | 66.0 |

Notes: 1. Orders received in the Chemicals Business do not include pharmaceutical excipients and food preservatives, which are manufactured based on sales plans rather than specific orders.
2. Orders received are based on selling prices; inter-segment transactions have been eliminated.
3. Orders received do not include consumption taxes.
(2) Order backlog
(Thousands of yen)

| Operating segment | First nine months of FY2/17 <br> (Mar. 1, 2016 - Nov. 30, 2016) |  | First nine months of FY2/18 <br> (Mar. 1, 2017 - Nov. 30, 2017) |  |
| :---: | ---: | ---: | ---: | ---: |
|  | Amount | Year-on-year (\%) | Amount | Year-on-year (\%) |
|  | $9,288,900$ | 116.5 | $7,681,872$ | 82.7 |
| Chemicals Business | 419,761 | 111.4 | 131,081 | 31.2 |
| Total | $9,708,661$ | 116.2 | $7,812,953$ | 80.5 |

Notes: 1. Order backlog in the Chemicals Business do not include pharmaceutical excipients and food preservatives, which are manufactured based on sales plans rather than specific orders.
2. Order backlog is based on selling prices; inter-segment transactions have been eliminated.
3. Order backlog does not include consumption taxes.

## (3) Sales

(Thousands of yen)

| Operating segment | First nine months of FY2/17 <br> (Mar. 1, 2016 - Nov. 30, 2016) |  | First nine months of FY2/18 <br> (Mar. 1, 2017 - Nov. 30, 2017) |  |
| :---: | ---: | ---: | ---: | ---: |
|  | Amount | Composition (\%) | Amount | Composition (\%) |
|  | $10,003,630$ | 67.7 | $9,747,293$ | 70.9 |
| Chemicals Business | $4,763,438$ | 32.3 | $3,998,649$ | 29.1 |
| Total | $14,767,069$ | 100.0 | $13,745,942$ | 100.0 |

Notes: 1. Sales are based on selling prices; inter-segment transactions have been eliminated.
2. Sales do not include consumption taxes.

This summary report is solely a translation of "Kessan Tanshin" (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.

